All articles by Vijay Madhukar Singavarapu

Vijay Madhukar Singavarapu

M&As this week: Strides Pharma Science, Lambda Therapeutic Research, NextPharma

Strides Pharma Science’s step-down subsidiary Strides Pharma has made an arrangement to acquire Vensun Pharmaceuticals for $18m.

Deals this week: Medicines for Malaria Venture, Swedish Orphan Biovitrum, aTyr Pharma

Medicines for Malaria Venture (MMV) has entered a collaboration with Drugs for Neglected Disease initiative (DNDi) to create a pandemic response box.

Deals and M&As this week: Alnylam Pharmaceuticals, Novartis

Alnylam Pharmaceuticals has entered an agreement with Medison Pharma to commercialise its RNAi therapeutic Onpattro in Israel.

M&As this week: ProKidney, Quest Products, Gencore Pacific

ProKidney has acquired inRegen and its subsidiary Twin City Bio.

Deals this week: Sanofi, Knight Therapeutics, Ascletis Pharma

Sanofi has gained access to Biomunex Pharmaceuticals’ Plug-and-Play BiXAb platform through a licensing agreement.

M&As this week: Takeda, Eli Lilly, Claudio Bidco

Takeda Pharmaceutical has completed an acquisition of Shire for $62bn.

Deals this week: Sanofi, Biogen, Janssen Pharmaceuticals

Sanofi and Regeneron Pharmaceuticals have entered a revised agreement for the development of novel cancer treatments.

Deals and M&As this week: EQT, Sanofi, Bristol-Myers Squibb

EQT has agreed to increase its acquisition offer for Karo Pharma to Skr6.15bn ($694m) through the EQT VIII fund.

M&As this week: Astellas Pharma, Taisho Pharmaceuticals, AMAG Pharmaceuticals

Astellas Pharma has completed the acquisition of Potenza Therapeutics for $405m.

Deals this week: GlaxoSmithKline, Incyte, Novo Nordisk

GlaxoSmithKline (GSK) and Pfizer have agreed to combine their consumer healthcare businesses with combined annual sales of £9.8bn ($12.7bn) and establish a joint venture (JV).